Inovio Pharmaceuticals (INO) acquires the global (ex-China) rights to therapies for Alzheimer's disease and multiple sclerosis based on the work of DNA researcher Dr. Ben Wang from Fudan University's Shanghai Medical College.
The therapies work by generating inducible regulatory T cells (iTreg). The cells are involved in shutting down immune responses after they have successfully eliminated invading organisms. They have potential in preventing autoimmune and inflammatory diseases.
No financial terms are disclosed.